Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple Sclerosis
Retrieved on:
Thursday, March 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Safety, Attention, Multiple sclerosis, Volunteering, Single, Senior, MAD, Company, IND, MS, Pharmacokinetics, Even and odd functions, Total survey error, Food, CNS, Neurodegeneration, Investigational New Drug, Inflammatory demyelinating diseases of the central nervous system, Learning, Patient, SAD, US Foods, Nerve, Therapy, PK, Program, CEO, Veps, Adult, Neuro, LinkedIn, Pharmaceutical industry, Pipeline, PIPE-307 for Multiple Sclerosis, Pipeline Therapeutics, PIPE-307 FOR MULTIPLE SCLEROSIS, PIPELINE THERAPEUTICS
Currently, there are no approved medicines that support myelin restoration, which represents a significant unmet medical need in the treatment of MS.
Key Points:
- Currently, there are no approved medicines that support myelin restoration, which represents a significant unmet medical need in the treatment of MS.
- The Phase 1 clinical results reported today comprised multiple dose cohorts of PIPE-307 in a total of 70 healthy volunteer subjects.
- We believe that PIPE-307, as a first-in-class myelin restoration therapeutic, represents a differentiated and clinically-validated approach for the treatment of MS.
- These encouraging Phase 1 results give us great confidence to advance PIPE-307 into clinical studies with MS patients as soon as possible.